Technology FAQs

Home>FAQs>Technology FAQs

How is Cartherics advancing cell therapy?

Cartherics has two autologous CAR-T products, treating cutaneous T cell lymphoma and ovarian cancer, entering clinical trials in 2023-24. The lead allogeneic product is expected to enter clinical trials for ovarian cancer in 2025. There is a pipeline of additional products focused on solid tumours following close behind. The Cartherics platform is expected to bring […]

2022-11-28T14:32:47+11:00November 28th, 2022||

How is Cartherics technology different to other immunotherapy treatments?

The Cartherics allogeneic (off-the-shelf) technology is based on umbilical cord blood cells from rare histocompatible donors that are converted to stem cells (iPSCs) and gene edited to introduce CARs and to knock-out genes that inhibit immune function. These are then converted into CAR-T or CAR-NK cells to enhance the patients’ own immune system to combat […]

2022-11-28T14:32:13+11:00November 28th, 2022||

How does the technology work?

Chimeric antigen receptors (CARs) are antibody fragments linked to activation molecules, that recognise molecules specifically present on the surface of cancer cells. These CAR complexes are genetically engineered into the immune cell (T cell or NK cell) genome and expressed on their surface. When the antibody fragment engages with the cancer cell, the activation molecules […]

2022-11-28T14:31:07+11:00November 28th, 2022||

What does Cartherics do?

Cartherics is a biotechnology company focused on developing innovative cancer therapies. We have developed CAR-T cells that are derived from the blood of cancer patients that are genetically modified and expanded for their therapy for blood (cutaneous T cell lymphoma) and solid tumours (ovarian and gastric cancers).  Our primary focus is now on therapies that […]

2022-11-28T14:35:47+11:00November 24th, 2022|, |
Go to Top